Clinical trial • Cardiology
DEXAMETHASONE DISODIUM PHOSPHATE for Ischaemic heart disease | Valvular heart disease
Clinical trial of DEXAMETHASONE DISODIUM PHOSPHATE for Ischaemic heart disease | Valvular heart disease.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Ischaemic heart disease | Valvular heart disease
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 29-09-2024
- First CTIS Authorization Date
- 23-10-2024
Trial design
Randomised, dexamethasone (dexavit, injection/infusion solution) versus placebo (solution for injection); olanzapine (olanzapine glenmark europe 20 mg orodispersible tablets) versus placebo (tablet); flow-targeted versus pressure-targeted hemodynamic management during cpb (no drug); low tidal volume ventilation versus no ventilation during cpb. dexamethasone max daily amount listed as 20 mg; olanzapine max daily amount listed as 10 mg. specific dosing schedule not specified.-controlled trial across 3 sites in Denmark.
- Randomised
- Yes
- Comparator
- Dexamethasone (Dexavit, injection/infusion solution) versus placebo (solution for injection); Olanzapine (Olanzapine Glenmark Europe 20 mg orodispersible tablets) versus placebo (tablet); flow-targeted versus pressure-targeted hemodynamic management during CPB (no drug); low tidal volume ventilation versus no ventilation during CPB. Dexamethasone max daily amount listed as 20 mg; Olanzapine max daily amount listed as 10 mg. Specific dosing schedule not specified.
- Target Sample Size
- 1200
- Trial Duration For Participant
- 180
Eligibility
Recruits 1200 No vulnerable population selected; participants are adults (above 18). Informed consent is required from participants; assent not applicable..
- Pregnancy Exclusion
- Pregnancy or currently breastfeeding
- Vulnerable Population
- No vulnerable population selected; participants are adults (above 18). Informed consent is required from participants; assent not applicable.
Inclusion criteria
- {"criterion_text":"-Adult, i.e., above 18 years of age\n-Scheduled for CABG and/or AVR, irrespective of other concomitant valve surgery."}
Exclusion criteria
- {"criterion_text":"-Acute surgery (i.e. off hours surgery)\n-Recipient of any major organ transplant\n-Obstructive hypertrophic cardiomyopathy, active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism\n-Having received cytotoxic/cytostatic chemotherapy or radiation therapy for treatment of malignancy within the last 6 months\n-Clinical evidence of current malignancy except for basal or localized squamous cell carcinoma, cervical intraepithelial neoplasia or stable prostate cancer.\n-Known narrow-angle glaucoma\n-Known phenylketonuria\n-Pregnancy or currently breastfeeding\n-Known endocarditis at time of screening\n-Previous participation in the trial\n-Active infection, including bacterial, viral, and/or fungal infection\n-Known hepatic cirrhosis\n-Known severe thrombocytopenia with thrombocyte levels < 50 x 109/L\n-Known severe neutropenia with neutrocyte levels < 2 x 109/L\n-On the waiting list for a heart transplant\n-Type I diabetes\n-Known long QT syndrome\n-Known allergy for any of the included study drugs\n-Any condition, where participation in the study, in the investigator's opinion could put the subject at risk, confound the study results or interfere significantly with participation in the study\n-Patients with extracardiac arteriopathy (assessed as part of the preoperative EuroSCORE) will be excluded from the intervention 'flow-targeted vs. pressure-targeted hemodynamic management during CPB'."}
Endpoints
Primary endpoints
- {"endpoint_text":"-The primary endpoint will be number of days alive and outside hospital within 90 days after surgery.","definition_or_measurement_approach":"Number of days alive and outside hospital within 90 days after surgery (days alive outside hospital within 90 days)."}
Secondary endpoints
- {"endpoint_text":"-Time in days to occurrence of any component in a composite secondary endpoint during follow-up: a) Death from any cause, b) Stroke, c) Acute kidney injury or d) New onset or worsening heart failure\n-Severe post-operative complications during index admission, defined as a Clavien-Dindo class of 3 to 5.\n-Delirium during the first 7 days after surgery, defined as a positive Confusion Assessment Method for the ICU (CAM-ICU) score or a positive Confusion Assessment Method (CAM) score for the general wards\n-Quality of Recovery-15 (QoR-15) score 3 days, or as soon as possible, after surgery\n-90-day outcomes: Survival, Change in modified Rankin Scale (mRS) from baseline, Health-related quality of life (EQ-5D-5L), Change in self-perceived function \"two simple questions\" and Days alive outside ICU\n-180-day outcomes: Survival","definition_or_measurement_approach":"Composite endpoint: time in days to first occurrence of death, stroke, acute kidney injury, or new/worsening heart failure. Severe complications defined as Clavien-Dindo class 3-5. Delirium defined by CAM-ICU or CAM. QoR-15 measured at day 3 (or as soon as possible). 90-day outcomes include survival, mRS change, EQ-5D-5L, self-perceived function, and days alive outside ICU. 180-day outcome is survival."}
Recruitment
- Planned Sample Size
- 1200
- Recruitment Window Months
- 74
- Consent Approach
- Informed consent obtained using provided subject information and informed consent forms (L1_ICF and related documents). Participants are adults; assent not applicable.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 1200
Denmark
- Earliest CTIS Part Ii Submission Date
- 11-10-2024
- Latest Decision Or Authorization Date
- 27-02-2026
- Processing Time Days
- 504
- Number Of Sites
- 3
- Number Of Participants
- 1200
Sites
- Site Name
- Aarhus Universitet
- Department Name
- Dept. of Cardiothoracic and Vascular Surgery, Anaesthesia Section
- Principal Investigator Name
- Peter Juhl-Olsen
- Principal Investigator Email
- petejuhl@rm.dk
- Contact Person Name
- Peter Juhl-Olsen
- Contact Person Email
- petejuhl@rm.dk
- Site Name
- Rigshospitalet
- Department Name
- Dept. of Cardiothoracic Anaesthesiology
- Principal Investigator Name
- Sebastian Wiberg
- Principal Investigator Email
- sebastian.christoph.wiberg@regionh.dk
- Contact Person Name
- Sebastian Wiberg
- Contact Person Email
- sebastian.christoph.wiberg@regionh.dk
- Site Name
- Odense University Hospital
- Department Name
- Department of Anesthesia & Intensive Care Medicine
- Principal Investigator Name
- Simon Mølstrøm
- Principal Investigator Email
- simon.molstrom@rsyd.dk
- Contact Person Name
- Simon Mølstrøm
- Contact Person Email
- simon.molstrom@rsyd.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"1","organisation_type":"Educational Institution"}
Investigational products
- Investigational Product Name
- Dexavit, injektions-/infusionsvæske, opløsning
- Active Substance
- DEXAMETHASONE DISODIUM PHOSPHATE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS USE
- Route
- intravenous
- Authorisation Status
- Authorised (marketing authorisation 55739)
- Maximum Dose
- 20 mg
- Investigational Product Name
- Olanzapine Glenmark Europe 20 mg orodispersible tablets
- Active Substance
- OLANZAPINE
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Authorisation Status
- Authorised (EU marketing authorisation EU/1/09/588/012)
- Maximum Dose
- 10 mg
- Investigational Product Name
- PLACEBO (solution for injection)
- Active Substance
- PLACEBO
- Modality
- Other
- Routes Of Administration
- INTRAVENOUS USE
- Route
- intravenous
- Maximum Dose
- 20 mg
- Investigational Product Name
- PLACEBO (tablet)
- Active Substance
- PLACEBO
- Modality
- Other
- Routes Of Administration
- ORAL USE
- Route
- oral
- Maximum Dose
- 10 mg
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- METHYLPREDNISOLONE for Fulminant myocarditis
- PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease
- clopidogrel for Acute coronary syndrome | Cardiovascular diseases
- APIXABAN for Venous thromboembolism
- SOTAGLIFLOZIN for Obstructive hypertrophic cardiomyopathy | Non-obstructive hypertrophic cardiomyopathy